FDA ENANTIOMER MARKETING EXCLUSIVITY POLICY MAY BE REVISED, AGENCY ANNOUNCES; WYETH/INTERNEURON REDUX EXCLUSIVITY DETERMINATION TO BE MADE BY PTO, FDA SAYS

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".